Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (12,3 Mio. €): NEUES GRAM-NEGATIVES ANTIBIOTIKUM JETZT Hor20.06.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
NEUES GRAM-NEGATIVES ANTIBIOTIKUM JETZT
AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics. Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| 441.359 € | |
| EVOTEC INTERNATIONAL GmbH | 0,00 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 1.198.125 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 331.835 € |
| Glaxosmithkline Investigacion y Desarrollo SL | 0,00 € |
| HELMHOLTZ-ZENTRUM für INFEKTIONSFORSCHUNG GmbH | 1.268.750 € |
| Institut National de la Sante et de la Recherche Medicale | 185.663 € |
| Medizinische Universitaet Wien | 730.571 € |
| 2.422.556 € | |
| Nosopharm | 4.098.421 € |
| Stichting Lygature | 725.681 € |
| The University of Liverpool | 897.034 € |
| Universite de Poitiers | 0,00 € |
Quelle: https://cordis.europa.eu/project/id/853979
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Bioaster Fondation de Cooperation Scientifique - EU-Förderung (12,3 Mio. €): NEUES GRAM-NEGATIVES ANTIBIOTIKUM JETZT"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
